Advisory Services Network LLC Has $6.93 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Advisory Services Network LLC lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,156 shares of the company’s stock after selling 306 shares during the quarter. Advisory Services Network LLC owned 0.06% of Medpace worth $6,934,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Medpace by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock worth $783,626,000 after acquiring an additional 142,591 shares during the last quarter. Riverbridge Partners LLC boosted its position in Medpace by 7.1% during the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock worth $199,975,000 after acquiring an additional 43,197 shares during the last quarter. TD Asset Management Inc boosted its position in Medpace by 195.2% during the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after acquiring an additional 308,816 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Medpace by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after buying an additional 319,210 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Medpace by 82.3% in the 4th quarter. Epoch Investment Partners Inc. now owns 352,463 shares of the company’s stock valued at $108,040,000 after buying an additional 159,144 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Thursday. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and increased their price objective for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. TD Cowen began coverage on Medpace in a report on Wednesday, May 29th. They issued a “buy” rating and a $452.00 price objective for the company. Robert W. Baird increased their price target on Medpace from $456.00 to $469.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $445.29.

Medpace Trading Up 1.8 %

MEDP stock traded up $8.01 during trading hours on Friday, hitting $443.00. 61,344 shares of the stock were exchanged, compared to its average volume of 227,467. The firm has a market capitalization of $13.72 billion, a P/E ratio of 44.34, a P/E/G ratio of 2.07 and a beta of 1.36. The company has a 50-day simple moving average of $400.06 and a two-hundred day simple moving average of $373.77. Medpace Holdings, Inc. has a 12 month low of $227.21 and a 12 month high of $444.87.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.27 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 4,782 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the transaction, the chief executive officer now owns 716,197 shares in the company, valued at $286,894,194.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO August J. Troendle sold 3,987 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the transaction, the chief executive officer now owns 660,351 shares in the company, valued at $260,983,922.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 4,782 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the transaction, the chief executive officer now owns 716,197 shares in the company, valued at approximately $286,894,194.26. The disclosure for this sale can be found here. Insiders have sold 29,621 shares of company stock worth $11,816,852 in the last 90 days. Company insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.